Lutris Pharma Israeli Company
Lutris Pharma is developing the topical B-Raf inhibitor LUT014, a proprietary small molecule allowing administration of epidermal growth factor receptor (EGFR) inhibitors to patients without the interruptions caused by typical cutaneous side effects.
Health Tech & Life Sciences
Biotechnology
First Aid
Health Care
Wellness
Alternatives
No alternatives listed yet.
Suggest an Alternative
Founders
Parent Companies/Investors
References
[1]
finder.startupnationcentral.org
- https://finder.startupnationcentral.org/company_page/lutris-pharma
[2]
crunchbase.com
- https://www.crunchbase.com/organization/lutris-pharma
External links are provided for reference and verification purposes.